HAMILTON, Bermuda, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets ...

HAMILTON, Bermuda, April 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological ...

Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Sanj Patel, CEO & Chairman of the Board, stated that "Year-to-date, in 2025, we've continued to execute and ...

Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the results of three studies which supported the U.S. Food and Drug Administration ...

ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy Regeneron plans to file by mid-2011 for ...

Arcalyst saw only modest sequential growth in the first quarter due to the usual seasonal headwinds at the start of the year, but that did not stop Kiniksa from raising the guidance range at the time ...

CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...

Kiniksa Pharmaceuticals reports Q1 2025 net revenue of $137.8 million for ARCALYST, forecasts 2025 revenue of $590-$605 million. Kiniksa Pharmaceuticals reported significant financial growth in Q1 ...

Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...

Regeneron announced results from its second Phase 3 study of Arcalyst (rilonacept) for the treatment of gout patients initiating allopurinol therapy. This trial, known as the global PRE-SURGE 2 ...